Incanthera (AQSE:INC) Asset Impairment Charge : £0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Asset Impairment Charge?

Incanthera's Asset Impairment Charge for the six months ended in Sep. 2023 was £0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 was £0.00 Mil.

Incanthera Asset Impairment Charge Historical Data

The historical data trend for Incanthera's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Asset Impairment Charge Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Asset Impairment Charge

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Asset Impairment Charge	Get a 7-Day Free Trial			-	-	-	-	-

Incanthera Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Incanthera Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Incanthera's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines